MedTrace Logo

Efficacy and Safety of Oral Encochleated Amphotericin B for the Treatment of Cryptococcal Infection

NCT03196921 · Status: WITHDRAWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL

Last updated 2019-03-08

No results posted yet for this study

Summary

This will be an open label phase I/II prospective cohort study to determine the efficacy and safety of CAMB for the treatment and prevention of cryptococcal infection.

Conditions

  • Cryptococcal Infections

Interventions

DRUG

Encochleated Amphotericin B

lipid-crystal nanoparticle formulation of amphotericin B; oral

Sponsors & Collaborators

Principal Investigators

  • David R Boulware, MD, MPH · University of Minnesota

  • Tafese Beyene Tufa · Asella Teaching Hospital, Arsi University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-10-01
Primary Completion
2019-10-01
Completion
2020-03-01
FDA Drug
Yes

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03196921 on ClinicalTrials.gov